
They’ve got a Golden Ticket: Alceus Bio wins 2025 initiative
Biotechnology company Alceus Bio has been awarded Pioneer Group and AbbVie’s 2025 Golden Ticket. The company, a developer of synthetic chimeric antigen receptor T-lymphocyte therapies for solid malignancies, was chosen as the winner after an extensive selection process. The Golden Ticket provides a significant package of… Read More


